Repligen Brings In $458.6 Million Cash And Moves Exchanged Debt To 2031
The completed financing carries 0.25% annual interest, while approximately $143.2 million of the 2028 notes remains outstanding.
Repligen, which sells equipment and consumable products used to manufacture biological drugs, brought in approximately $458.6 million in cash Friday through a completed convertible-debt financing that also replaced part of its debt due in 2028. The company issued $1.0 billion of new notes in the previously announced private transactions, according to its SEC filing.
Cash Plus A Larger Debt Exchange
The cash subscriptions accounted for approximately $458.6 million of the new debt. The exchange portion accounted for approximately $541.4 million: investors received those new notes for approximately $456.8 million of the old notes, which Repligen canceled.
That leaves approximately $143.2 million of the 2028 debt in place, with its terms unchanged. The exchange moves the replaced borrowing to a November 1, 2031 maturity, but the principal issued in that portion exceeds the principal retired.
The new notes carry annual interest of 0.25%, compared with 1% on the exchanged debt. They are senior unsecured obligations—borrowing backed by no pledged collateral—and may be converted, redeemed or repurchased before maturity.
Cash First, Shares For The Excess
The initial conversion price is approximately $226.37 per share. That represents an approximately 20% premium to RGEN shares’ $188.64 closing price on Thursday, October 29, on the Nasdaq Global Select Market.
Conversion requires Repligen to settle principal in cash. For conversion value above principal, the company can choose cash, shares or a mixture, so any share issuance depends on how that excess is settled.
Initially, a maximum of 5,301,100 shares may be issued upon conversion. That ceiling includes additional shares potentially deliverable under specified corporate-change or redemption provisions and remains subject to anti-dilution adjustments.
Before August 1, 2031, holders can convert only when specified stock-price, note-trading-price, redemption or corporate-event conditions are met. From that date, conversion becomes available without those conditions until the contractual cutoff before maturity.
The Biological-Drug Supply Business
Repligen’s business spans filtration, chromatography, process analytics and proteins used in making monoclonal antibodies, vaccines, and cell and gene therapies. Most revenue comes from consumable and single-use products; customers include biopharmaceutical companies, contract drug manufacturers, diagnostics businesses and laboratory researchers.
The Waltham, Massachusetts-based company operates 19 manufacturing sites and had about 2,000 employees as of December 31, 2025. North America supplied 49% of its 2025 revenue, with Europe contributing 34%.
The first interest payment is due May 1, 2027, with subsequent payments each May 1 and November 1.
Sources
- 8-K Filing — REPLIGEN CORP (RGEN) — SEC EDGAR
- Exhibit rgen-20261106xexx41.htm — REPLIGEN CORP 8-K exhibit — SEC EDGAR